Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9921185 | European Journal of Pharmacology | 2005 | 5 Pages |
Abstract
Selegiline, a monoamine oxidase-B inhibitor, is reported to improve memory and learning in dementia of Alzheimer's type. However, only a few studies have reported its use in animal models. Here, we evaluated the effects of selegiline only or its combined use with donepezil, a selective acetylcholinesterase inhibitor on memory impairment, using a Morris water maze. Selegiline dose-dependently attenuated ethylcholine aziridinium ion-induced memory impairment. Co-administration of selegiline and donepezil, at doses that do not exert efficacy individually, significantly ameliorated scopolamine + p-chlorophenylalanine-induced memory deficits. These results suggest that selegiline improves memory impairment mediated by the cholinergic system, and provide evidence of the usefulness of co-treatment with selegiline and donepezil for treating spatial deficits in dementia.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Kazue Takahata, Akiko Minami, Haruko Kusumoto, Seiichiro Shimazu, Fumio Yoneda,